Report #2846746

Received Jun 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: NJ
Recovered: Unknown
Vaccinated: Mar 1, 2025
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	—	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Inappropriate schedule of vaccine administered; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose in 2022). In MAR-2025, the patient received the 2nd dose of Shingrix. In MAR-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Inappropriate schedule of vaccine administered). In MAR-2025, the outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 11-JUN-2025 The patient received 2nd dose at longer interval than recommended which led to lengthening of vaccination schedule.